Company news

Tyra Biosciences, Inc. news in 2026

Tyra Biosciences, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Tyra Biosciences to Participate in Upcoming Investor Conferences

November 5, 2026

Tyra Announces Pricing of $400 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

September 14, 2026

Tyra Biosciences Reports Initial Phase 2 SURF302 Results Supporting the First Potential Oral Innovation in LG IR NMIBC with Dabogratinib

September 9, 2026

Tyra Biosciences to Present at the Cantor Global Healthcare Conference

September 8, 2026

Tyra Biosciences to Host Conference Call on Initial Results of Oral Dabogratinib from the SURF302 Phase 2 Study for IR NMIBC on September 9, 2026

September 4, 2026

Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights

August 4, 2026

TYRA Biosciences and BCAN establish May 21 as upper tract urothelial cancer (UTUC) awareness day

May 21, 2026

Tyra Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights

May 13, 2026

Tyra Biosciences Announces Appointment of Habib Dable to its Board of Directors

April 17, 2026

Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights

March 2, 2026

Tyra Biosciences Announces Poster Presentations at the 2026 ASCO® Genitourinary (GU) Cancers Symposium

February 23, 2026

Decks in 2026